Update: September 2023 - Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV has been updated as follow:

September 14, 2023

Mycobacterium tuberculosis

• Added recommendations for dolutegravir- and raltegravir-based antiretroviral (ARV) regimens in the context of tuberculosis (TB) disease for children >20 kg and <20 kg, respectively. 
• Added references to American Academy of Pediatrics (AAP) guidance that recommends interferon-gamma release assays (IGRAs) to diagnose latent tuberculosis infection (LTBI) in children ≥2 years old.
• Added recommendations that children ≥2 years old with HIV infection who are receiving ARV regimens with acceptable drug-drug interactions with rifapentine can receive the 12-dose isoniazid-rifapentine LTBI treatment regimen.